Delivery Order SPE2DB24D1021-SPE2DB25FFAQW
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Vyvanse 10 mg capsules (100 count) under contract number 4569458763. The order, valued at $14,907.14, carries a firm fixed price and is scheduled for completion by September 15, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet federal procurement requirements in open competition. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,253.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,372.32 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work is to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $23,405.42 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This non-set-aside, firm fixed-price delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count units) valued at $1,876.30 under a firm fixed price contract type. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAQWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 10 mg capsules (100-count units) under a firm fixed price contract on September 12, 2025, with a ceiling value of $1,337.70 and ultimate completion date of September 15, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor for federal medical procurement, leveraging the company's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The order will be fulfilled from AmerisourceBergen's distribution facilities in Conshohocken, Pennsylvania. This award exemplifies AmerisourceBergen's extensive partnership with the Defense Logistics Agency for supplying medications across multiple therapeutic domains to military and veteran healthcare systems. Vyvanse, a prescription stimulant medication, represents the type of neurological and specialty pharmaceutical product that falls within the company's comprehensive product portfolio under its global pharmaceutical support vehicle. As a child delivery order under the larger DLA prime vendor contract, this transaction demonstrates the flexibility and efficiency of the indefinite delivery contract mechanism in supporting routine pharmaceutical procurement needs for the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/12/25 |